AdvanDx, Inc. Launches First LNA-Based In Vitro Diagnostic Test for Detection of Antibiotic Resistant 'Superbugs'
AdvanDx, Inc.announced the launch of vanA/B EVIGENE in Europe, the first LNA-based in vitro diagnostic test for detecting the antibiotic resistant 'Superbugs' Vancomycin-Resistant Enterococci (VRE) and Vancomycin-Resistant Staphylococcus aureus (VRSA) in positive blood cultures and clinical isolates. Infections with antibiotic resistant 'Superbugs', such as VRE and VRSA, are serious problems for patients and hospitals worldwide. Rapid and accurate identification of these pathogens is crucial to ensuring early, appropriate and effective therapy that will allow hospitals to reduce mortality, patient length of stay and overall costs while in the long run tackling the problem of antibiotic resistance.
According to the company, vanA/B EVIGENE combines the high specificity of Locked Nucleic Acid (LNA) probes with EVIGENE, a signal amplified sandwich hybridization assay platform, to rapidly and accurately detect both the vanA and vanB genes that confer vancomycin resistance in enterococci and Staphylococcus aureus. A study published by the Centers for Disease Control and Prevention in the Journal of Clinical Microbiology concluded that the EVIGENE technology demonstrated 100% sensitivity and specificity for the detection of vanA in S. aureus (VRSA) and vanA or vanB in enterococci (VRE).
"We are extremely excited to see AdvanDx introduce the first LNA-based in vitro diagnostic test. This marks the transition of LNA from a research tool to a clinical diagnostic tool," said Dr. Henrik Stender, Vice President for Research and Development, at AdvanDx.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Analysis by AlgoNomics reveals that Anticalins have an immunogenicity level comparable to the wild-type human lipocalin
Cellectis Acquires Vectocell Technology to Accelerate Therapeutic Development Programs
New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis - Menveo (MenACWY-CRM) the first quadrivalent conjugated meningitis vaccine to demonstrate an excellent immune response in infants
Kentucky Bioprocessing, Icon Genetics and Mapp Biopharmaceutical have entered into discussions to merge their businesses
